Business
Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH)
– Once-weekly TransCon® CNP and TransCon® hGH combination therapy showed durable growth without compromising safety or tolerability at 52 weeks – Annualized growth velocity (AGV) exceeded the 97th-percentile of average stature children – ACH height Z-score improvements indicated a tripling of efficacy compared to TransCon CNP monotherapy – Combination therapy demonstrated benefits beyond linear growth with improvements in body proportionality and arm span, aligning with the increase in linear gr
About this update from Ascendis Pharma A/s
[{"type":"image","alt":"Ascendis Pharma","displaySize":"","headline":null,"caption":"Ascendis Pharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":100,"url":"https://media.zenfs.com/en/globenewswire.com/7afd0e29f0a4b40bcd5ff718a81f4afe"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1tA.9j4XDPXN.zyLsOvv6w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/7afd0e29f0a4b40bcd5ff718a81f4afe","width":300,"height":100}},"lazy":false},{"type":"text","content":"– Once-weekly TransCon® CNP and TransCon® hGH combination therapy showed durable growth without compromising safety or tolerability at 52 weeks","length":143,"tagName":"p"},{"type":"text","content":"– Annualized growth velocity (AGV) exceeded the 97th-percentile of average stature children ","length":91,"tagName":"p"},{"type":"text","content":"– ACH height Z-score improvements indicated a tripling of efficacy compared to TransCon CNP monotherapy ","length":103,"tagName":"p"},{"type":"text","content":"– Combination therapy demonstrated benefits beyond linear growth with improvements in body proportionality and arm span, aligning with the increase in linear growth","length":164,"tagName":"p"},{"type":"text","content":"– All children completed 52 weeks of treatment and remain on therapy in COACH as of today","length":89,"tagName":"p"},{"type":"text","content":"– Combination therapy was generally well tolerated, with generally mild treatment-emergent adverse events (TEAEs), consistent with TransCon CNP and TransCon hGH monotherapies","length":174,"tagName":"p"},{"type":"text","content":"– Ascendis to host conference call today at 4:30pm ET ","length":53,"tagName":"p"},{"type":"text","content":"COPENHAGEN, Denmark, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced topline results from Week 52 of COACH, the first Phase 2 clinical trial to evaluate combination therapy with once-weekly TransCon CNP (navepegritide) and once-weekly TransCon hGH (lonapegsomatropin) in children with achondroplasia. At Week 52, combination therapy showed durable growth without compromising safety or tolerability. In addition, combination therapy demonstrated benefits beyond linear growth with improvements in body proportionality and arm span, aligning with the increase in linear growth. Safety and tolerabil...